secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009147
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Takeda notifies Ovid of soticlestat Phase 3 delays; primary completion March 2024
--------------------------------------------------------------------------------

- Takeda notified Ovid that two pivotal Phase 3 soticlestat trials (Dravet & Lennox-Gastaut) are likely delayed due to Ukraine/Russia and China COVID lockdowns.
- Primary completion date now estimated March 2024; regulatory filings expected in Takeda's fiscal 2024.
- Takeda stated studies remain highest-priority late-stage programs; actively recruiting with multiple approaches to minimize delays.
- Ovid retains significant financial interest in soticlestat's development and potential commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017022009147/0000950170-22-009147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017022009147/ovid-20220510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer